LifeSci Capital Initiates Coverage of Aimmune Therapeutics

Developing the Oral Immunotherapy AR101 for Desensitization of Peanut Allergies; Report Available here: http://www.lifescicapital.com/equity-research/aimmune/

NEW YORK, NY / ACCESSWIRE / June 10, 2016 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of Aimmune Therapeutics (NasdaqGS: AIMT), a biopharmaceutical company developing allergy desensitization treatments for patients with peanut and other food allergies. No therapies are available to address the growing prevalence of severe peanut allergies, leaving these patients at risk of life-threatening anaphylaxis upon accidental exposure to peanuts. Aimmune’s lead product candidate is AR101, a proprietary peanut formulation based on the Company’s characterized oral desensitization immunotherapy (CODIT) platform.

The alarming rise in peanut and other food allergies is undisputed. In the past 13 years allergists have witnessed the peanut allergy rate more than quadruple. More than 5 million children and adults are estimated to have peanut allergies. Currently, there is no approved treatment for those with peanut allergies, and the looming risk of deadly reactions to an often hidden food product has spurred a demand for potentially life-saving desensitization therapies.

Aimmune’s Phase II data demonstrate that patients who underwent AR101 immunotherapy were able to withstand peanut exposure at amounts in excess of a typical event of accidental dietary exposure. This success positions Aimmune to be the first in class offering an efficacious peanut desensitization therapy that may protect peanut allergic individuals from life threatening anaphylactic episodes. Our estimates indicate that even modest penetration of the peanut allergy market could lead to sales for AR101 of more than $1 billion per year.

In a 38 page Initiation Report LifeSci Capital explains the scientific rationale behind Aimmune’s clinical program, provides estimates for the peanut allergy market, and discusses the clinical data generated to date, as well as that of competitors.

Dr. Isaacson’s full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on Aimmune as developments occur.

The LifeSci Capital research team is led by Dr. Jerry Isaacson, an industry veteran with broad experience in biotechnology, having worked in both public and private biotech companies in areas ranging from medicinal chemistry and analytical chemistry to patents and investor/public relations. Dr. Isaacson holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego.

About LifeSci Capital:

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients’ businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company’s website, www.lifescicapital.com.

Analyst Contact:

Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: jisaacson@lifescicapital.com

SOURCE: LifeSci Capital, LLC

ReleaseID: 441027